Introduction
Plasma dexamethasone levels are an important variable in understanding hypothalamicpituitary-adrenal (HPA) axis dysregulation in psychiatrically disturbed adults. Investigators have found that depressed adults who are nonsuppressors on the dexamethasone suppression test (DST) have significantly lower plasma dexamethasone concentrations than depressed patients and control subjects who are DST suppressors (Johnson et al. 1984; Arana et al. 1984; Maguire et al. 1987) . Several explanations have been advanced for this observation. Lowy and Meltzer (1987) raised the possibility that bioavailability of dexamethasone pla3s ,~ ma~or r~!e in determining DST suppressor status and have suggested that simultaneous measurement of plasma dexamethasone and cortisol levels are needed to evaluate DST results. Alternatively, Holsboer and associates (1986a and b) concluded that the low plasma dexamethasone levels in nonsuppressing adult depressives were due to accelerated metabolism of dexamethasone rather than impaired bioavailability, and suggested that the abnormality of glucocorticoid nactabolism in depressives with DST nonsuppression is state-dependent.
Although the plasma dexamethasone variable has not been studied in children, the association between suppressor status and dexamethasone dose has been. In a study of 97 children aged 3 to 16 years, Doberty and co-workers (1986) found no significant difference in the percentage of depressed children who failed to suppress at high, medium, or low doses of dexamethasone based on body weight. We undertook this study to exan~ine the relationship between plasma dexamethasone levels and DST suppressor status in children. We hypothesized that: (1) psychiatrically disturbed children with DST nonsuppression would have lower plasma dexamethasone levels than DST suppressors regardless of diagnosis; and (2) dexamethasone dosage would ccrrelate directly with plasma dexamethasone levels and inversely with plasma cortisol levels.
Methods

Patients
Seventy-three children (aged 5-14 years) admitted to the Diagnostic and Research Unit at the University of Michigan Hospitals were administer~ ~:he dexamethasone suppression test (DST), regardless of diagnosis. Exclusion criteria for the DST wen as described by Carroll et al. (1981) . Demographic data are presemed in Table 1 . Major depressive disorder was the primary diagnosis in 14 children, dysthymic disorder in 11, adjustment disorder with depressed mood in 2, attention deficit disorder with hyperactivity in 11, anxiety disorder in 6, conduct disorder in 13, oppositional disorder in 3, schizophrenia in 1, adjustment disorder with mixed disorder of mood and conduct in 3, pervasive developmental disorder in 3, psychosomatic disorder in 3, ~a0 personality disorder in 2.
We initially divided the population into DST suppressors and nonsuppressors and subsequently subdivided the population into depressed (major depressive disorder and dysthymic disorder) and nondepressed (all other diagnoses). The 2 children diagnosed as having an adjustment disorder with depiessed mood were assigned to the nondepressed group (both were DST suppressors, and analysis of the data with these 2 children categorized as depressed did not change the results).
Diagnostic Procedure
Each child was rigorously evaluated medically and psychiatrically. Height and weight were recorded and body surface area was determined according to the method of Gehan ana George (1970) . Each patient and his or her family were interviewed by a senior staff ps~,,niatrist and a fellow in child psychiatry. Developmental and family history were obtained in the initial interview, and academic history was obtained from the child's school teacher. Further diagnostic information obtained during the first 2 weeks of hospitalization included neuropsychologicai e~d psychological testing, milieu observations, and reports from the hospital's school. Consensual diagnoses were made after 2 weeks of hospitalization based on all available information according to unmodified DSM-HI criteria.
DST Procedure
The DST was performed within the first week of hospitalization. All patients were medication free for at least 2 weeks before having the DST. After we obtained informed consent from the parents and assent from the child when possible, we drew a baseline cortisol level at 11:00 PM on day 1, then gave each subject dexamethasone. For children weighing less than 36 kg, we administered 0.5 mg of dexamethasone as described by Poznansld et al. (1982) . This dosage was based on the ration'de that the children would receive approximately the same dose of dexamethasone on a mg./kg basis that ~n averagesized adult would receive. Children weighing 36 kg or more were given 1.0 mg as described by Carroll et al. (1981) . Thirty-eight children received 0.5 mg of dexamethasone whereas 35 received 1.0 mg. Children were observed closely by the nursing staff to assure they had taken the dexamethasone tablets. Plasma cortisol, obtained on day 2 at 4:00 PM, was measured by a competitive protein binding assay with interassay coefficients of variation of 7.6, 6.2, and 5.0% at 4.0, 8.0, and 16.0 ILg/dl of cortisol, respectively, and intra-assay coefficients of variation of 7.1, 5°8, and 4.7% for the same plasma cortisol values. DST nonsuppression was defined as a postdcxamethasone plasma cortisol ~> 5.0 ttg/dl at 4:00 PM. Concurrent plasma dexamethasone levels were obtained and quantified by a radioimmunoassay technique using rabbit antiserum produced against a bovir.c ~er-m albumin conjugate of dexamethasone hemisuccinate. The rabbit antiserum for the DST assay was provided by Merck Sharpe and Dohme. The sensitivity of the assay is 100 pg/ ttl using 100 ttl of plasma and is reliable at plasma dexamethasone levels greater than or equal to 10 ng/dl. The assay is highly specific for dexamethasone with no cortisol cross-reactivity until the concentration of cortisol exceeds 16-18 ttg/dl. Interassay coefficients of variation are 6.5 and 5.0% at 109 and 380 ng/dl of dexamethasone, respectively. The intra-assay coefficients of variation are 5.5 and 4.8% for the same values.
Data Analysis
To test the hypothesis that psychiatrically hospitalized children with DST nonsuppression have lower plasma dexamethasone levels than suppressors, we divided the total sample into DST suppressors and nonsuppressors and compared plasma dexamethasone levels between them using an unpaired, one-tailed t-test. We chose a one-tailed test as we postulated a specific directionality to the results and to reduce the likelihood of a Type I error, (incorrectly rejecting a tree hypothesis). To determine whether the diagnosis of depression was a significant variable, we further subdivided the sample into depres~,ed and nondepressed subjects and conducted the same analyses.
To analyze the data continaously as well as dichotomously, and to test the hypothesis that dexamethasone dosage would correlate directly with plasma dexamethasone and inversely with postdexamethasone cortisol levels, we calculated Pearson's r correlation coefficients using dexamethasone dosage as one variable and plasma dexamethasone L,," plasma cortisoi, respectively, as the second variable. Because plasma dexamethasone levels and postdexamethasone cortisol levels were not normally distributed, we log transformed the data before all analyses. For all statistical analyses, we accepted p values of <0.05 as significant.
Results
Plasma Dexamethasone Levels
DST nonsuppressors had significantly lower (p < 0.03) plasma dex~nethasone levels than suppressors (Table 2) . When the total sample was divided according to the presence or absence of depression, both depressed and nondepressed DST nonsuppressors showed a similar trend towards having lower plasma dexamethasone levels; however, these findings failed to reach statistical significance (Figure l) . Fifteen of the 18 nonsuppressors received 0.5 mg of dexamethasone (5 with depression and l0 with other diagnoses). Of the 3 nonsuppressors given 1.0 mg, 2 were depressed. X2-analysis of the data revealed no differences in gender distribution between the various groups, suggesting that gender was not a major variable affecting plasma dexamethasone levels or DST suppressor status. As shown in Table 3 , mg/m 2 dose of dexamethasone was directly correlated with plasma dexamethasone levels for the total sample (p < 0.003) and for DST suppressors (p < 0.04), and inversely correlated with 4:00 PM postdexarnethasone plasma cortisol levels for the total sample (p < 0.04). There was no correlation between mg/kg dexamethasone dose and plasma dexamethasone concentrations or postdexamethasone cortisol levels. We found a statistically significant inverse correlation between plasma dexamethasone levels and postdexamethasone cortisol levels for the total sample (p < 0.04) and for DST suppressors (p < 0.0001). We found no significant correlations between dexamethasone dosage and plasma dexamethasone or cortisol concentrations, or between plasma dexamethasone concentrations and postdexamethasone plasma conisol levels in DST nonsuppressors.
As shown in Tables I and 2 , DST nonsuppressors were significantly younger, lighter, and smaller, and received less dexamethasone, either absolute or expressed in terms of mg/m 2, than suppressors.
Discussion
The results of thaw ~tudy support our hypothesis that DST nonsuppression in children is associated with low plasma dexamethasone levels when compared with DST suppressors. Our hypothesis that dexamethasone dosage is directly correlated with plasma dexamethasone levels and inversely with plasma cortisol levels was also supported. Mg/m 2, but not mg/kg, dexamethasone dose was directly correlated with plasma dexamethasc.ne levels in the total sample and DST suppressors, and inversely correlated with postdexamethasone cortisol concentrations in the total sample. We demonstrated an inverse correlation between plasma dexamethasone levels and postdexamethasone plasma cortisol concentrations for the total sample. Interestingly, however, we found no significant correlation among dexamethasone dosage and plasma dexamcthasone or cortisol concentrations, or between plasma dexamethasone levels and cortisol concentrations in DST nonsuppressors.
It is not possible with this study design to address the question of why plasma dexamethasone levels were lower in DST nonsuppressors than in suppressors. Dexamethasone dosage likely accounts for part of the difference. As a group, nonsuppressors received significantly smaller mg and mg/m 2 dexamethasone doses than DST suppressors. Age, height, weight, and size differences may also account for part of the difference. Nonsuppressors were younger, smaller, and lighter than suppressors, and it may be that younger, smaller children metabolize dexamethasone more rapidly than older, larger ones. There is only minimal current support for this hypothesis; however, Richter et al. (1983) found that toddlers have lower plasma dexamethasone concentrations than adults after administration of equivalent doses of dexamethasone when corrected for weight--which offers tentative support. Finally, the lack of significant correlation between plasma dexamethasone levels and postdexamethasone cortisol levels in DST nonsuppressors suggests that hypothalamic-pituitary-adrenal axis dysregulation and altered glucocorticoid metabolism may account for the observed difference in plasma dexamethasone levels between suppressors and nonsuppressors.
The findings of this study must be interpreted with caution. There were no normal controls for comparison with our patient subgroups. Additionally, patients were not randomized to dosage groups nor were they administered both dosages of de×amethasone. Finally, severity and duration of the illness were not accounted for in the study design. Future studies are necessary to determine the influence of severity and duration of illness, age, and size on glucocorticoid metabolism and consequently, dexamethasone suppressor status in depressed children. Nevertheless, these data are consistent with those obtained from adults.
This study has several implications for researchers in child psychiatry. The effect of dexamethasone dose, and subsequently plasma dexamethasone concentrations, on postdexamethasone plasma cortisol levels and DST suppressor status underscores the need for standardization of the DST protocol in children. At least 5 dexamethasone dosage strategies have been used by child psychiatric researchers including the modified 0.5 mg DST (Poznanski et al. 1982) , the standard 1.0 mg DST (Carroll et al. 1981) , assignment of dexamethasone dosage based on a strict weight cut-off (Jensen and co-workers 1985) , the use of a 20 ttg/kg dose for all patients (Geller et al. 1983) , and assignment of dexamethasone dose based on pubertal status (Emslie and co-workers 1987) . This lack of standardization makes generalization among studies very difficult. The use of a rag/ m 2 dose of dexamethasone may be warranted on the basis of our findings and may aid in the standardization of the DST in children. Meanwhile, simultaneous measurement of plasma dexamethasone and postdexamethasone cortisol levels is indicated to determine the effects of various plasma dexamethasone levels on DST suppressor status.
